Gliptin-induced bullous pemphigoid: withdrawal of gliptin allows for faster control of the disease
Sign Up to like & getrecommendations! Published in 2022 at "European Journal of Dermatology"
DOI: 10.1684/ejd.2022.4270
Abstract: Gliptins, also called dipeptidyl peptidase-4 inhibitors, have been incriminated in the development of bullous pemphigoid (BP). To date, there are no recommendations regarding the therapeutic approach for BP during gliptin intake. The aim of this… read more here.
Keywords: bullous pemphigoid; three months; complete response; gliptin ... See more keywords
Use of gliptins reduces levels of SDF-1/CXCL12 in bullous pemphigoid and type 2 diabetes, but does not increase autoantibodies against BP180 in diabetic patients
Sign Up to like & getrecommendations! Published in 2022 at "Frontiers in Immunology"
DOI: 10.3389/fimmu.2022.942131
Abstract: The use of dipeptidyl peptidase 4 (DPP4) inhibitors, (also known as gliptins), is associated with an increased risk of bullous pemphigoid (BP), an autoimmune blistering skin disease. To explore the mechanism behind gliptin-associated BP we… read more here.
Keywords: bullous pemphigoid; sdf cxcl12; bp180; type diabetes ... See more keywords